Merus N.V.
NASDAQ: MRUS
NYSE
NYSE
Healthcare
Biotechnology
Global Rank
#3906
Country Rank
n/a
Market Cap
3.89 B
Price
56.21
Change (%)
0.36%
Volume
761,713
Merus N.V.'s latest marketcap:
3.89 B
As of 06/07/2025, Merus N.V.'s market capitalization has reached $3.89 B. According to our data, Merus N.V. is the 3906th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 3.89 B |
| Revenue (ttm) | 54.73 M |
| Net Income (ttm) | -277,344,000 |
| Shares Out | 69.21 M |
| EPS (ttm) | -4.14 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 07/31/2025 |
Market Cap Chart
Data Updated: 06/07/2025
Merus N.V.'s yearly market capitalization.
Merus N.V. has seen its market value grow from $300.6 M to $3.89 B since 2016, representing a total increase of 1,194.24% and an annual compound growth rate (CAGR) of 35.46%.
| Date | Market Cap | Change (%) |
|---|---|---|
| 06/07/2025 | $3.89 B | 34.66% |
| 12/31/2024 | $2.88 B | 81.33% |
| 12/29/2023 | $1.59 B | 121.65% |
| 12/30/2022 | $716.3 M | -41.96% |
| 12/31/2021 | $1.23 B | 142.03% |
| 12/31/2020 | $509.9 M | 55.03% |
| 12/31/2019 | $328.9 M | 20.92% |
| 12/31/2018 | $272 M | -12.85% |
| 12/29/2017 | $312.1 M | 3.83% |
| 12/30/2016 | $300.6 M |
Company Profile
About Merus N.V.
Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, specializing in the development of innovative antibody therapeutics.
Pipeline Highlights
- BIZENGRI: A bispecific antibody candidate targeting pancreatic adenocarcinoma and non-small cell lung cancer (NSCLC), excluding Neuregulin 1.
- MCLA-158: In development for the treatment of solid tumors.
- MCLA-129: Designed to address lung and other solid tumors.
- ONO-4685: Focused on relapsed/refractory T cell lymphoma.
- INCA33890: Targeting advanced solid tumors.
Strategic Collaborations
Merus has established key partnerships with industry leaders, including:
- Eli Lilly and Company
- Ono Pharmaceutical Co., Ltd.
- Betta Pharmaceuticals Co. Ltd.
Founded in 2003, Merus N.V. operates from its headquarters in Utrecht, the Netherlands.
Frequently Asked Questions
-
What is Merus N.V.'s (MRUS) current market cap?As of 06/07/2025, Merus N.V. (including the parent company, if applicable) has an estimated market capitalization of $3.89 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Merus N.V. (MRUS) rank globally by market cap?Merus N.V. global market capitalization ranking is approximately 3906 as of 06/07/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.